- Home
- EAD vs HUMAW Comparison
EAD vs HUMAW Comparison
Compare EAD & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | HUMAW |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.8M | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EAD | HUMAW |
|---|---|---|
| Price | $6.74 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 178.9K | 14.2K |
| Earning Date | 01-01-0001 | 03-21-2025 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.69 | $1.18 |
| 52 Week High | $6.81 | $1.34 |
Technical Indicators
Market Signals| Indicator | EAD | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 36.05 |
| Support Level | $6.76 | $0.11 |
| Resistance Level | $6.80 | $0.15 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.